fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-09-03
Biotech partner: Ipsen (France) Santhera Pharmaceuticals (Switzerland)
Type of agreement: * commercialization/ distribution
* development
Compound: Fipamezole (antagonist of the adrenergic alpha-2 receptor)
Disease area: levodopa-induced dyskinesia in Parkinson’s Disease
Development phase: Initiation of a first Phase III study by Biovail, Santhera’s North American partner, is scheduled for 2011 (See agreements)
Nature of the agreement: Santhera Pharmaceuticals and Ipsen have concluded a license agreement for the development and commercialization of fipamezole for territories outside of North America and Japan.
The first Phase III study is scheduled for 2011 in the treatment of levodopa induced dyskinesia. Santhera has the right to use and sublicense data generated by Biovail for development and commercialization purposes outside of the United States and Canada. This agreement stipulates that Ipsen has acquired the right to use these data for its own development and commercialization purposes outside the United States, Canada and Japan, whereas the Japanese rights for fipamezole remain with Santhera.

Financial terms of the agreement: Under the agreement, Ipsen acquires the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of €13 million and additional payments contingent to future development, regulatory and sales milestones of up to €128 million. In addition, Santhera is entitled to royalty payments on Ipsen’s future net sales.

Go back to previous page